Mirum Pharmaceuticals Inc (MIRM)
24.07
-0.68
(-2.75%)
USD |
NASDAQ |
May 17, 16:00
24.07
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Cash from Financing (TTM): 324.82M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 324.82M |
December 31, 2023 | 336.60M |
September 30, 2023 | 334.49M |
June 30, 2023 | 213.43M |
March 31, 2023 | 103.97M |
December 31, 2022 | 109.09M |
September 30, 2022 | 110.03M |
June 30, 2022 | 24.31M |
March 31, 2022 | 84.98M |
Date | Value |
---|---|
December 31, 2021 | 73.47M |
September 30, 2021 | 207.36M |
June 30, 2021 | 209.11M |
March 31, 2021 | 143.22M |
December 31, 2020 | 181.29M |
September 30, 2020 | 46.78M |
June 30, 2020 | 113.10M |
March 31, 2020 | 171.84M |
December 31, 2019 | 127.18M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
24.31M
Minimum
Jun 2022
336.60M
Maximum
Dec 2023
161.95M
Average
135.20M
Median
Cash from Financing (TTM) Benchmarks
Vanda Pharmaceuticals Inc | -- |
Sarepta Therapeutics Inc | 45.35M |
Puma Biotechnology Inc | 0.00 |
Reneo Pharmaceuticals Inc | 59.86M |
Tharimmune Inc | 11.52M |